company background image
ATQP logo

Vericel DB:ATQP Stock Report

Last Price

€56.50

Market Cap

€2.8b

7D

5.6%

1Y

39.9%

Updated

02 Feb, 2025

Data

Company Financials +

Vericel Corporation

DB:ATQP Stock Report

Market Cap: €2.8b

ATQP Stock Overview

A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. More details

ATQP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 42.84% per year

Became profitable this year

Risk Analysis

Volatile share price over the past 3 months compared to the German market


My Notes

Capture your thoughts, links and company narrative

Vericel Corporation Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€946.4m

Heidelberg Pharma

XTRA:HPHA

€111.4m

Gerresheimer

XTRA:GXI

€2.3b

Price History & Performance

Summary of share price highs, lows and changes for Vericel
Historical stock prices
Current Share PriceUS$56.50
52 Week HighUS$58.00
52 Week LowUS$35.80
Beta1.73
1 Month Change5.61%
3 Month Change40.55%
1 Year Change39.85%
3 Year Change94.83%
5 Year Change260.45%
Change since IPO126.00%

Recent News & Updates

Recent updates

Shareholder Returns

ATQPDE BiotechsDE Market
7D5.6%1.0%1.9%
1Y39.9%-4.3%15.1%

Return vs Industry: ATQP exceeded the German Biotechs industry which returned -4.3% over the past year.

Return vs Market: ATQP exceeded the German Market which returned 15.1% over the past year.

Price Volatility

Is ATQP's price volatile compared to industry and market?
ATQP volatility
ATQP Average Weekly Movement8.0%
Biotechs Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ATQP's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: ATQP's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1989314Nick Colangelovcel.com

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel Corporation Fundamentals Summary

How do Vericel's earnings and revenue compare to its market cap?
ATQP fundamental statistics
Market cap€2.79b
Earnings (TTM)€3.42m
Revenue (TTM)€218.84m

814.4x

P/E Ratio

12.7x

P/S Ratio

Is ATQP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATQP income statement (TTM)
RevenueUS$226.84m
Cost of RevenueUS$64.73m
Gross ProfitUS$162.12m
Other ExpensesUS$158.57m
EarningsUS$3.55m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.072
Gross Margin71.47%
Net Profit Margin1.56%
Debt/Equity Ratio0%

How did ATQP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 07:59
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vericel Corporation is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeAscendiant Capital Markets LLC
Michael GormanBTIG
William PlovanicCanaccord Genuity